Welcome to Crene Biotechnology!

+86-576-88205808

EMA Panel Backs Roclanda Eyedrops, New Option for Glaucoma
Release time:2020-11-17 01:45:00

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of latanoprost and netarsudil (Roclanda).

The ophthalmic solution is indicated to decrease elevated intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil fails, according to an EMA news release.

 

Reference:

https://www.medscape.com/viewarticle/941062?src=rss

 


Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China